PI 0824
Alternative Names: Peptide immunotherapy - Peptimmune; PI-0824Latest Information Update: 19 Jul 2010
At a glance
- Originator Peptimmune
- Class Peptides; Skin disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pemphigus vulgaris
Most Recent Events
- 13 Dec 2007 Orphan Europe has been acquired by Recordati
- 15 Nov 2006 Peptimmune and Orphan Europe have entered into an agreement to co-promote and co-develop PI 0824 for Pemphigus vulgaris
- 31 May 2005 Peptimmune has completed a phase trial in Pemphigus vulgaris in USA